Compare · MRK vs REGN
MRK vs REGN
Side-by-side comparison of Merck & Company Inc. (MRK) and Regeneron Pharmaceuticals Inc. (REGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and REGN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $329.65B, about 3.5x REGN ($95.24B).
- Over the past year, MRK is up 36.8% and REGN is up 21.9% - MRK leads by 14.9 points.
- REGN has been more active in the news (26 items in the past 4 weeks vs 25 for MRK).
- Both have 25 recent analyst ratings on file.
- Company
- Merck & Company Inc.
- Regeneron Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $329.65B
- $95.24B
- 1M return
- -9.16%
- +12.42%
- 1Y return
- +36.81%
- +21.93%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 1991
- News (4w)
- 25
- 26
- Recent ratings
- 25
- 25
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Latest MRK
- Merck Announces TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoint of Overall Survival (OS) in Third-Line or Later Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma
- Merck and Isomorphic Labs Enter Strategic Research Collaboration
- Merck & Company Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director
- Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib
- Merck Announces First-Quarter 2027 Dividend
- EVP&Pres, Merck Animal Heallth Deluca Richard R. exercised 58,185 shares at a strike of $77.62 and sold $8,611,875 worth of shares (58,185 units at $148.01), decreasing direct ownership by 0.00% to 112,955 units (SEC Form 4)
- SEC Form 13F-HR filed by Merck & Company Inc.
- Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
- Merck to Participate in the Jefferies Global Healthcare Conference in London
Latest REGN
- SEC Form S-8 filed by Regeneron Pharmaceuticals Inc.
- FDA Approval for LIVSAYIS issued to REGENERON PHARMACEUTICALS
- Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)
- Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing
- Director George L Sing sold $1,917,945 worth of shares (2,000 units at $958.97), decreasing direct ownership by 8% to 23,147 units (SEC Form 4)
- EVP Commercial Marion Mccourt sold $543,504 worth of shares (566 units at $960.25) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 10,305 units (SEC Form 4)
- Co-Chief Scientific Officer Andrew J Murphy exercised 17,000 shares at a strike of $381.92, covered exercise/tax liability with 11,989 shares and sold $4,799,336 worth of shares (5,011 units at $957.76) as part of a pre-agreed trading plan (SEC Form 4)
- Libtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer Indications
- POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms
- CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD